Kim Branson, PhD

Dr. Kim Branson is SVP, Global Head, AI/ML at GSK, based in San Francisco.  Kim leads the GSK.ai team, a global organization of nearly 100 machine learning researchers and engineers who are pioneering the application of AI to drug discovery and development. Kim brings a deep expertise in modeling and machine learning to drug and vaccine discovery, combining perspectives spanning academia to technology start-up. Under his leadership, GSK has built one of the industry’s few completely in-house AI efforts to unlock the potential of complex genetic data and leverage GSK’s industry-leading collaborations. Kim joined GSK in 2019 from Genentech where he was Head of AI, Early Clinical Development. Kim has been involved in large-scale machine learning and medical informatics initiatives for more than 20 years  over a range of ventures from computational drug design to disease risk prediction. Previously Kim helped found several Silicon Valley start-ups, including Discovery Engine (acquired by Twitter in 2009), Gliimpse as Chief Scientist (acquired by Apple in 2017), and Lumiata, a predictive health analytics company. Kim received degrees from the University of Adelaide and a PhD from the University of Melbourne. He was a Peter Doherty fellow and received postdoctoral training at Stanford University.